本帖最后由 老马 于 2013-3-13 13:43 编辑 3 B5 g, G4 N+ E3 ]2 M L6 u
' y$ I! F0 E% V" V8 g健择（吉西他滨）+顺铂+阿瓦斯汀
9 a9 M% m! T0 v5 H9 U; e0 L X/ q Gemzar +Cisplatin + Avastin' @7 ?0 I$ S( n8 B& ]5 a' E W, t
http://annonc.oxfordjournals.org/content/21/9/1804.full
4 q( W/ U" x3 t) A1 fOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 4 i. Z1 S1 Y" M% i* @8 O
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. * y. u' r" k: [3 N d8 a
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 4 W" r) e5 K, ~& p% L8 \. {
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1140)
3 {5 ?& i& F& j
华为网盘附件：- x, l7 w: c& m, Y, k5 z. W
【华为网盘】ava.JPG
$ O4 R8 K: s/ `$ ]. f7 Z |
11011102001537 )
显身卡
